Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT06353022 | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma(IFm2022-01) | active not recruiting | Phase 2 | 103 | Nantes University Hospital |
| 1 |
| Mar 17, 2026 |
| clinicaltrials |
| NCT07477912 | Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma(MSTH-CAR001) | recruiting | Phase 1 / Phase 2 | 30 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05767359 | CAR- PRISM (PRecision Intervention Smoldering Myeloma) | active not recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05896228 | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma(Iber-KDd) | recruiting | Phase 2 | 30 | Benjamin T Diamond, MDOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04094961 | Ixazomib + Pomalidomide + Dexamethasone In MM | active not recruiting | Phase 1 / Phase 2 | 52 | Omar Nadeem, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04656951 | Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse(GMMG-DADA) | active not recruiting | Phase 2 | 67 | University of CologneOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04802356 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | active not recruiting | Phase 2 | 50 | PETHEMA FoundationOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06066346 | A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07169500 | Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03589222 | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | active not recruiting | Phase 2 | 62 | PETHEMA FoundationOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04764942 | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | active not recruiting | Phase 1 / Phase 2 | 39 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06235229 | A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma(DURGA-3) | recruiting | Phase 1 / Phase 2 | 110 | Gracell Biotechnologies (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 68 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05530421 | Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma(SELVEDge) | recruiting | Phase 2 | 33 | University of MiamiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06100237 | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)(REVIVE) | recruiting | Phase 2 | 50 | Carl Ola Landgren, MD, PhDOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06711705 | Elranatamab in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 33 | University of California, San DiegoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07421856 | Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. | not yet recruiting | Phase 1 / Phase 2 | 24 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 0 | Feb 19, 2026 | clinicaltrials |
| NCT04977024 | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | active not recruiting | Phase 2 | 63 | GeoVax, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05396885 | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)(iMMagine-1) | active not recruiting | Phase 2 | 136 | Kite, A Gilead CompanyINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06015542 | Self-administration of Subcutaneous Elranatamab in the Patients' Homes.(ERICA) | recruiting | Phase 2 | 20 | Thomas LundOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04850846 | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | active not recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03933735 | A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 220 | AbbVieINDUSTRY | 2 | Feb 6, 2026 | clinicaltrials |
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | recruiting | Phase 2 | 127 | Karyopharm Therapeutics IncINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT04240054 | Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency(VICD) | recruiting | Phase 2 | 41 | Medical College of WisconsinOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT02718833 | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 52 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 | Jan 16, 2026 | clinicaltrials |
| NCT07348393 | A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(Mezi-KD) | not yet recruiting | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05922501 | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma(ISABELA) | recruiting | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03030261 | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 25 | Washington University School of MedicineOTHER | 2 | Jan 12, 2026 | clinicaltrials |
| NCT06910124 | Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse | recruiting | Phase 2 | 32 | Dickran Kazandjian, MDOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT01746849 | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04991103 | Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | recruiting | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07312188 | A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 2 | 90 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma(IZALCO) | active not recruiting | Phase 2 | 118 | SanofiINDUSTRY | 7 | Dec 29, 2025 | clinicaltrials |
| NCT05130827 | Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05695508 | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5(HD10/DSMMXX) | recruiting | Phase 2 | 160 | University of Heidelberg Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | active not recruiting | Phase 2 | 79 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05801939 | Cevostamab Following CAR T Cell Therapy for RRMM | active not recruiting | Phase 2 | 30 | University of PennsylvaniaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04268199 | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment(EASE) | recruiting | Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06518551 | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | recruiting | Phase 1 / Phase 2 | 49 | Omar Nadeem, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06645678 | Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma(MELT-MM) | recruiting | Phase 1 / Phase 2 | 75 | YOUNGIL KOHOTHER | 2 | Dec 3, 2025 | clinicaltrials |
| NCT06920251 | Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy(OPTIMUS-EL) | recruiting | Phase 2 | 40 | Seoul National University HospitalOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06947083 | Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | recruiting | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04174196 | A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | active not recruiting | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07188090 | Mozobil for Autologous Hematopoietic Stem Cell Transplantation(HSCT) | recruiting | Phase 2 | 100 | Thomas Jefferson UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02253316 | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | active not recruiting | Phase 2 | 236 | Washington University School of MedicineOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03315026 | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2026source: clinicaltrials